Lyme vaccine demonized by advocacy groups
(Impact Factor: 41.46).
04/2006; 440(7082):278. DOI: 10.1038/440278b
Available from: Edward Mcsweegan
Epidemiology and Infection 02/2007; 135(1):9-10. DOI:10.1017/S0950268806007394 · 2.54 Impact Factor
Available from: aldf.com
[Show abstract] [Hide abstract]
ABSTRACT: This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult vaccination schedule and the potential need for boosters; class action lawsuits; uncertainty regarding risk of disease; and low public demand. This article reviews lessons learned from these events and proposes that future candidate Lyme disease vaccines are unlikely to be developed, tested, and used within the United States in the near future, thus leaving at-risk populations unprotected.
Clinical Infectious Diseases 02/2011; 52 Suppl 3(Supplement 3):s253-8. DOI:10.1093/cid/ciq116 · 8.89 Impact Factor
Lyme Borreliosis in Europe and North America: Epidemiology and Clinical Practice, 07/2011: pages 225 - 244; , ISBN: 9780470933961
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.